Yu Holly, Alfred Tamuno, Zhou Jingying, Judy Jennifer, Olsen Margaret A
Health Economics and Outcomes Research, Pfizer Inc, Collegeville, PA, USA.
Statistical Research and Data Science Center, Pfizer Inc, New York, NY, USA.
Antimicrob Steward Healthc Epidemiol. 2024 Dec 11;4(1):e215. doi: 10.1017/ash.2024.400. eCollection 2024.
To estimate incidence and healthcare costs and mortality associated with infection (CDI) among adults <65 years old.
Retrospective cohort study.
First CDI episodes among commercially insured US patients 18-64 years old were identified from a large claims database. CDI+ patients were propensity score-matched (PSM) 1:1 with CDI- controls using clinically relevant variables including comorbidities.
Annual CDI incidence was calculated by age group and year (2015-2019). Healthcare utilization, costs, and mortality were analyzed by age group, acquisition (healthcare and community), and hospitalization status by calculating CDI-excess costs and mortality as the difference between PSM CDI+ and CDI- individuals.
In 50-64- and 18-49-year-olds, respective CDI incidence per 100,000 person-years decreased from 217 and 113 cases in 2015 to 167 and 87 cases in 2019. Most cases (76.5%-86.9%) were community-associated. The costs and mortality analyses included 6,332 matched CDI+/- 50-64-year-olds and 6,667 CDI+/- 18-49-year-olds. Among 50-64-year-olds, mean 2-month healthcare and patients' out-of-pocket costs were $11,634 and $573 higher, respectively, in the CDI+ versus CDI- group. Among 18-49-year-olds, 2-month costs were $7,826 and $642 higher. Healthcare costs were higher for healthcare- versus community-associated CDI. At the 12-month follow-up, mortality was significantly higher in the CDI+ versus CDI- groups for both 50-64-year-olds (4.2% vs 2.0%; < .001) and 18-49-year-olds (1.2% vs 0.6%; < .001). Mortality rates were higher for hospitalized versus nonhospitalized CDI+ patients.
Prevention of CDI among adults 18-64 years old may significantly reduce costs and mortality.
评估65岁以下成年人艰难梭菌感染(CDI)的发病率、医疗费用及死亡率。
回顾性队列研究。
从一个大型理赔数据库中识别出18 - 64岁商业保险美国患者的首次CDI发作。使用包括合并症在内的临床相关变量,将CDI+患者与CDI-对照按1:1倾向评分匹配(PSM)。
按年龄组和年份(2015 - 2019年)计算年度CDI发病率。通过计算PSM CDI+和CDI-个体之间的差异作为CDI超额成本和死亡率,按年龄组、感染源(医疗保健和社区)以及住院状态分析医疗保健利用、成本和死亡率。
在50 - 64岁和18 - 49岁人群中,每10万人年的CDI发病率分别从2015年的217例和113例降至2019年的167例和87例。大多数病例(76.5% - 86.9%)与社区相关。成本和死亡率分析纳入了6332例匹配的50 - 64岁CDI+/-患者和6667例18 - 49岁CDI+/-患者。在50 - 64岁人群中,CDI+组与CDI-组相比,平均2个月的医疗保健费用和患者自付费用分别高出11,634美元和573美元。在18 - 49岁人群中,2个月的费用高出7,826美元和642美元。与社区相关的CDI相比,医疗保健相关的CDI医疗费用更高。在12个月的随访中,50 - 64岁人群(4.